Journal of Shandong University (Health Sciences) ›› 2024, Vol. 62 ›› Issue (4): 92-100.doi: 10.6040/j.issn.1671-7554.0.2024.0118

• Clinical Medicine • Previous Articles    

Differentiation and molecular pathological analysis of motor neurons in a case of spinal muscular atrophy

LIU Wenzhu, LIU Fuchen   

  1. Department of Neurology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Published:2024-05-16

PDF (PC)

31

Abstract: Objective To explore the molecular pathologic phenotype of spinal and bulbar muscular atrophy(SBMA)using motor neurons derived from induced pluripotent stem cells(iPSCs)from SBMA patients. Methods Skin fibroblasts from one SBMA patient and one healthy control were extracted and reprogrammed into iPSCs; iPSCs were induced into motor neurons progenitor(MNP)and differentiated into mature motor neurons(mMN); immunofluorescence staining was used to study cell proliferation and apoptosis, and the formation of intranuclear inclusion bodies was detected. Results The patient was a 35-year-old male who presented with proximal weakness of the extremities, hand tremors, and hypogonadism. Skeletal muscle biopsy showed pathologic changes of neurogenic damage. Peripheral blood capillary electrophoresis showed 44 repeats of CAG in exon 1 of the AR gene. iPSCs all expressed stemness markers, had normal karyotypes, and were able to differentiate randomly into trichodermal cell types. No intranuclear inclusion bodies were seen in patient iPSCs and MNP, but intranuclear inclusion bodies were more typical in mMN. Compared with normal controls, the patients MNP had an increased proportion of apoptosis and a decreased proportion of proliferation. Conclusion The iPSCs of SBMA patients carried pathogenic mutations, and their differentiated mMNs contained typical intranuclear inclusion bodies, which accurately mimicked the molecular pathological features of the disease and provided an ideal model for the subsequent mechanism study and drug target discovery.

Key words: Spinal and Bulbar Muscular Atrophy, Kennedys Disease, Androgen Receptor Gene, Induced Pluripotent Stem Cells, Motor Neurons

CLC Number: 

  • R746.4
[1] Cortes CJ, La Spada AR. X-linked spinal and bulbar muscular atrophy: from clinical genetic features and molecular pathology to mechanisms underlying disease toxicity[J]. Adv Exp Med Biol, 2018, 1049: 103-133. doi: 10.1007/978-3-319-71779-1_5.
[2] Borgia D, Malena A, Spinazzi M, et al. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients[J]. Hum Mol Genet, 2017, 26(6): 1087-1103.
[3] Feng X, Luo S, Lu B. Conformation polymorphism of polyglutamine proteins[J]. Trends Biochem Sci, 2018, 43(6): 424-435.
[4] Minakawa EN, Nagai Y. Protein aggregation inhibitors as disease-modifying therapies for polyglutamine diseases[J]. Front Neurosci, 2021, 15: 621996. doi: 10.3389/fnins.2021.621996.
[5] Giorgetti E, Lieberman AP. Polyglutamine androgen receptor-mediated neuromuscular disease[J]. Cell Mol Life Sci, 2016, 73(21): 3991-3999.
[6] Querin G, Bertolin C, Da RE, et al. Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8): 810-816.
[7] Fratta P, Nirmalananthan N, Masset L, et al. Correlation of clinical and molecular features in spinal bulbar muscular atrophy[J]. Neurology, 2014, 82(23): 2077-2084.
[8] Hashizume A, Banno H, Katsuno M, et al. Quantitative assessment of swallowing dysfunction in patients with spinal and bulbar muscular atrophy[J]. Intern Med, 2017, 56(23): 3159-3165.
[9] Suzuki K, Katsuno M, Banno H, et al. The profile of motor unit number estimation(MUNE)in spinal and bulbar muscular atrophy[J]. J Neurol Neurosurg Psychiatry, 2010, 81(5): 567-571.
[10] Harding AE, Thomas PK, Baraitser M, et al. X-linked recessive bulbospinal neuronopathy: a report of ten cases[J]. J Neurol Neurosurg Psychiatry, 1982, 45(11): 1012-1019.
[11] Sobue G, Hashizume Y, Mukai E, et al. X-linked recessive bulbospinal neuronopathy. A clinicopathological study[J]. Brain, 1989,112( Pt 1): 209-232.
[12] Minakawa EN, Popiel HA, Tada M, et al. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation[J]. Brain, 2020,143(6): 1811-1825.
[13] Du ZW, Chen H, Liu H, et al. Generation and expansion of highly pure motor neuron progenitors from human pluripotent stem cells[J]. Nat Commun, 2015, 6: 6626. doi: 10.1038/ncomms7626.
[14] Giandomenico SL, Sutcliffe M,Lancaster MA.Generation and long-term culture of advanced cerebral organoids for studying later stages of neural development[J]. Nat Protoc, 2021, 16(2): 579-602.
[15] Wang D, Zhang R, Wang Y, et al. Establishment of an induced pluripotent stem cell(iPSC)line(INNDSUi001-A)from a healthy female Chinese Han[J]. Stem Cell Res, 2022, 62: 102819. doi: 10.1016/j.scr.2022.102819.
[16] Jamal A. Induced pluripotent stem cells(iPSCs): where are we and where are we heading?[J]. Cell Mol Biol(Noisy-le-grand), 2023, 69(11): 76-80.
[17] Sato M, Takizawa H, Nakamura A, et al. Application of urine-derived stem cells to cellular modeling in neuromuscular and neurodegenerative diseases[J]. Front Mol Neurosci, 2019, 12: 297. doi: 10.3389/fnmol.2019.00297.
[18] Petazzi P, Menendez P, Sevilla A. CRISPR/Cas9-mediated gene knockout and knockin human iPSCs[J]. Methods Mol Biol, 2022, 2454: 559-574. doi:10.1007/7651_2020_337.
[19] Fernandez-Guasti A, Kruijver FP, Fodor M, et al. Sex differences in the distribution of androgen receptors in the human hypothalamus[J]. J Comp Neurol, 2000, 425(3): 422-435.
[20] Li M, Sobue G, Doyu M, et al. Primary sensory neurons in X-linked recessive bulbospinal neuropathy: histopathology and androgen receptor gene expression[J]. Muscle Nerve, 1995,18(3): 301-308.
[21] Ward PJ, Davey RA, Zajac JD, et al. Neuronal androgen receptor is required for activity dependent enhancement of peripheral nerve regeneration[J]. Dev Neurobiol, 2021, 81(4): 411-423.
[22] Kumar R. Role of androgen receptor polyQ chain elongation in Kennedy's disease and use of natural osmolytes as potential therapeutic targets[J]. IUBMB Life, 2012, 64(11): 879-884.
[23] Mazzini L, Gelati M, Profico DC, et al. Human neural stem cell transplantation in ALS: initial results from a phase I trial[J]. J Transl Med, 2015,13: 17. doi: 10.1186/s12967-014-0371-2.
[24] Tadesse T, Gearing M, Senitzer D, et al. Analysis of graft survival in a trial of stem cell transplant in ALS[J]. Ann Clin Transl Neurol, 2014, 1(11): 900-908.
[25] Glass JD, Hertzberg VS, Boulis NM, et al. Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials[J]. Neurology, 2016, 87(4): 392-400.
[1] CHEN Wenbiao, YU Xiangqi, DAI Yong. Different expressions of novel microRNAs of iPSCs from Alport syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(9): 80-85.
[2] ZHANG Wen-hua, WU Cheng-yuan, LI Xin-gang, XU Shu-jun, LI Gang, JIANG Yu-quan, ZHOU Mao-de, LIU Meng . Gene therapy for amyotrophic lateral sclerosis in  a mouse model using a human glial cell linederived neurotrophic factor [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 25-29.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd